NR3C2 and Alzheimer disease: The AD‐HFpEF cohort was less likely to be treated with an angiotensin converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (38.5% versus 63.9%, P=0.001), but was more likely to be receiving an aldosterone receptor antagonist (25.6% versus 6.0%, P<0.001) or a loop diuretic (97.4% versus 77.1%, P<0.001).